Drug Trial Radar · NCT04386616
A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia
Last checked: Nov 19, 2026Latest source record: Jan 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
396
Actual
Start
Jun 2, 2020
Primary completion
Jan 8, 2021
Study completion Feb 12, 2021
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Biomedical Advanced Research and Development Authority
- First posted
- May 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) compared with placebo and of UTTR1147A compared with placebo, in combination with standard of care (SOC), in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.
Conditions
- COVID-19 Pneumonia
Interventions
MSTT1041ADrug
Participants received one intravenous (IV) infusion of MSTT1041A 700 milligrams (mg) on Day 1. A second IV dose of MSTT1041A 350 mg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
MSTT1041A-matched PlaceboDrug
Participants received up to 2 intravenous infusions of MSTT1041A-matched placebo.
UTTR1147ADrug
Participants received one intravenous (IV) infusion of UTTR1147A 90 micrograms/kilogram body weight (μg/kg) on Day 1. A second IV dose of UTTR1147A 90 μg/kg was given on Day 15 if the participant remained hospitalized with a requirement for supplemental oxygen.
UTTR1147A-matched PlaceboDrug
Participants received up to 2 intravenous infusions of UTTR1147A-matched placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to Recovery, Defined as the Time to a Clinical Status Score of 1 or 2 on the 7-Category Ordinal Scale (Whichever Occurs First) by Day 28Time frame: From Baseline up to 28 days
Locations
41 sites in 4 countries. Site status is shown where the registry gives one.
University of Arkansas For Medical Sciences
Little Rock, Arkansas
eStudySite - Chula Vista - PPDS
Chula Vista, California
eStudySite
La Mesa, California
Torrance Memorial Medical Center
Torrance, California
Denver Health Medical Center
Denver, Colorado
Bay Pines VA Medical Center - NAVREF
Bay Pines, Florida
WellStar Research Institute
Marietta, Georgia
DM Clinical Research - Alexandria Cardiology Clinic - ERN - PPDS
Alexandria, Louisiana
MedPharmics
Metairie, Louisiana
Southeast Louisiana Veterans Health Care System - NAVREF
New Orleans, Louisiana
Henry Ford Health System
Detroit, Michigan
St. Joseph'S Regional Medical Center
Paterson, New Jersey
San Juan Oncology Associates
Farmington, New Mexico
Albany Medical Center
Albany, New York
Staten Island University Hospital; Department of Pharmacy
Staten Island, New York
Lincoln Medical Mental Health Center
The Bronx, New York
Mercy St. Vincent Medical Center
Toledo, Ohio
Providence Portland Medical Center; Investigational Drug Services/Regional Research
Portland, Oregon
Lehigh Valley Health Network
Allentown, Pennsylvania
Parkland Health & Hospital System
Dallas, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Virginia Commonwealth University
Richmond, Virginia
Virginia Mason Medical Center
Seattle, Washington
MultiCare Institute for Research and Innovation; Clinic/Outpatient Facility
Tacoma, Washington
Instituto de Pesquisa Clinica Evandro Chagas FIOCRUZ
Rio de Janeiro, Rio de Janeiro, Brazil
Santa Casa de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Hospital E Maternidade Celso Pierro PUCCAMP
Campinas, São Paulo, Brazil
Hospital de Base Da Faculdade de Medicina de Sao Jose Do Rio Preto
São José do Rio Preto, São Paulo, Brazil
Hospital Alemao Oswaldo Cruz
São Paulo, São Paulo, Brazil
Instituto do Coração - HCFMUSP
São Paulo, São Paulo, Brazil
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
México, Mexico
Instituto Nacional De Enfermedades Respiratorias INER National Institute of Respiratory Diseases
México, Mexico
Hospital General de Tijuana
Tijuana, Mexico
Nuevo Hospital Civil de Guadalajara Dr. Juan I. Menchaca
Guadalajara, Jalisco, Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez
Monterrey, Nuevo León, Mexico
Hospital del Mar
Barcelona, Spain
Hospital General Universitario de Guadalajara
Guadalajara, Spain
Complejo Asistencial Universitario de Salamanca - H. Clinico
Salamanca, Spain
Hospital Clinico Universitario Valladolid
Valladolid, Spain
Hospital Universitario de Bellvitge
L'Hospitalet de Llobregat, Barcelona, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.